Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Affinivax","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"Affinivax Announces $120 Million Series B Financing to Advance Pipeline of Novel MAPS Vaccines and Immunotherapies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Affinivax","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affinivax Announces the Presentation of Phase 1 Clinical Data for its MAPS\u2122 Vaccine for Streptococcus pneumoniae at IDWeek 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Affinivax","sponsor":"Rock Springs Capital","pharmaFlowCategory":"D","amount":"$226.0 million","upfrontCash":"Undisclosed","newsHeadline":"Affinivax Announces $226 Million Series C Financing to Advance its Pipeline of Novel MAPS\u2122 Vaccines Targeting Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Affinivax","sponsor":"CARB-X","pharmaFlowCategory":"D","amount":"$22.0 million","upfrontCash":"Undisclosed","newsHeadline":"Affinivax Receives CARB-X for up to $22 Million to Advance its Staphylococcus aureus MAPS\u2122 Vaccine Candidate into Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Affinivax","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affinivax and Astellas Present Safety and Immunogenicity Data from Phase 2 Study of ASP3772","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Affinivax","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$4.5 million","upfrontCash":"Undisclosed","newsHeadline":"CEPI Partners with Affinivax to Develop a Novel COVID-19 Vaccine to Target Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery"},{"orgOrder":0,"company":"Affinivax","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$65.0 million","newsHeadline":"Affinivax Reacquires Rights from Astellas for ASP3772, a Novel 24-valent Streptococcus pneumoniae Vaccine Candidate from Affinivax\u2019s MAPS\u2122 Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Affinivax","sponsor":"CEPI","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affinivax to Highlight Preclinical Data from COVID-19 MAPS\u2122 Vaccine Development Program at IMMUNOLOGY 2022\u2122","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Affinivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affinivax Presents Data for Enhanced Protection Against Serotype 3 in Next-Generation Pneumococcal Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Affinivax","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$3,300.0 million","upfrontCash":"$2,100.0 million","newsHeadline":"GSK Completes Acquisition of Affinivax, Inc.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Affinivax

    Menu

    Affinivax

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Affinivax

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              GSK Completes Acquisition of Affinivax, Inc.

              Details:

              The acquisition of Affinivax with GSK’s strategy of building a portfolio of specialty medicines and vaccines. It includes a next-generation 24-valent pneumococcal vaccine ASP3772 (AFX3772), which is based on the innovative Multiple Antigen Presenting System (MAPS) platform.

              Lead Product(s): AFX3772

              Therapeutic Area: Infections and Infectious Diseases Product Name: ASP3772

              Highest Development Status: Phase I/ Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: GSK

              Deal Size: $3,300.0 million Upfront Cash: $2,100.0 million

              Deal Type: Acquisition August 16, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Affinivax

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Affinivax Presents Data for Enhanced Protection Against Serotype 3 in Next-Generation Pneumococcal Vaccine

              Details:

              Affinivax’s lead MAPS pneumococcal vaccine candidate is AFX3772, which has successfully completed a Phase 2 study in older adults, with a current clinical study in toddlers and planned study in infants.

              Lead Product(s): AFX3772

              Therapeutic Area: Infections and Infectious Diseases Product Name: ASP3772

              Highest Development Status: Phase I/ Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 21, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Affinivax

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Affinivax to Highlight Preclinical Data from COVID-19 MAPS™ Vaccine Development Program at IMMUNOLOGY 2022™

              Details:

              AFX3772, lead vaccine candidate targeting Streptococcus pneumoniae, developed using Affinivax’s proprietary MAPS™ (Multiple Antigen-Presenting System) technology platform, is designed to elicit both B-cell and T-cell immune protection.

              Lead Product(s): 24-Valent Pneumococcal Vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: AFX3772

              Highest Development Status: Preclinical Product Type: Vaccine

              Partner/Sponsor/Collaborator: CEPI

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 02, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Affinivax

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Affinivax Reacquires Rights from Astellas for ASP3772, a Novel 24-valent Streptococcus pneumoniae Vaccine Candidate from Affinivax’s MAPS™ Platform

              Details:

              Under the terms of the parties’ new agreement, the clinical development and commercialization of ASP3772, as well as royalties tied to the commercialization of Affinivax’s next generation pneumococcal vaccine products designed to treat Streptococcus pneuomoniae.

              Lead Product(s): 24-valent Streptococcus Pneumoniae Vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: ASP3772

              Highest Development Status: Phase I/ Phase II Product Type: Vaccine

              Recipient: Astellas Pharma

              Deal Size: Undisclosed Upfront Cash: $65.0 million

              Deal Type: Agreement February 28, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Affinivax

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CEPI Partners with Affinivax to Develop a Novel COVID-19 Vaccine to Target Variants

              Details:

              The collaborative program aims to establish preclinical proof of concept for a novel vaccine candidate designed to protect against new COVID-19 variants and that is also suitable for use in low- and middle-income countries.

              Lead Product(s): Covid-19 Vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Vaccine

              Partner/Sponsor/Collaborator: CEPI

              Deal Size: $4.5 million Upfront Cash: Undisclosed

              Deal Type: Partnership December 13, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Affinivax

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Affinivax and Astellas Present Safety and Immunogenicity Data from Phase 2 Study of ASP3772

              Details:

              The results from the Phase 2 clinical trial demonstrated that ASP3772 was well tolerated. ASP3772 also exhibited an antibody response to each of the 24 polysaccharides, as well as an additional antibody response to the conserved pneumococcal proteins.

              Lead Product(s): ASP3772

              Therapeutic Area: Infections and Infectious Diseases Product Name: ASP3772

              Highest Development Status: Phase I/ Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Astellas Pharma

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 12, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Affinivax

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Affinivax Receives CARB-X for up to $22 Million to Advance its Staphylococcus aureus MAPS™ Vaccine Candidate into Clinical Trials

              Details:

              Affinivax’s novel vaccine is being developed for the prevention of S. aureus infections, the most common form of staph infections, in high risk adult populations using the company’s Multiple Antigen Presenting System (MAPS™) vaccine technology platform.

              Lead Product(s): Staphylococcus aureus vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Vaccine

              Partner/Sponsor/Collaborator: CARB-X

              Deal Size: $22.0 million Upfront Cash: Undisclosed

              Deal Type: Funding March 09, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Affinivax

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Affinivax Announces $226 Million Series C Financing to Advance its Pipeline of Novel MAPS™ Vaccines Targeting Infectious Diseases

              Details:

              Affinivax’s novel and proprietary MAPS technology platform is designed to enable the development of a new class of vaccines that induce a broad and robust protective immune response to two key immunogenic components.

              Lead Product(s): ASP3772

              Therapeutic Area: Infections and Infectious Diseases Product Name: ASP3772

              Highest Development Status: Phase I/ Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Rock Springs Capital

              Deal Size: $226.0 million Upfront Cash: Undisclosed

              Deal Type: Series C Financing January 08, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Affinivax

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Affinivax Announces the Presentation of Phase 1 Clinical Data for its MAPS™ Vaccine for Streptococcus pneumoniae at IDWeek 2020

              Details:

              ASP3772 was observed to be safe and well tolerated in adults 18 to 64 years of age. ASP3772 exhibited robust immunogenicity to the 13 pneumococcal serotypes it shares in common with Prevnar13® as well as to an additional 11 serotypes included in ASP3772.

              Lead Product(s): ASP3772

              Therapeutic Area: Infections and Infectious Diseases Product Name: ASP3772

              Highest Development Status: Phase I/ Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Astellas Pharma

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 21, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Affinivax

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Affinivax Announces $120 Million Series B Financing to Advance Pipeline of Novel MAPS Vaccines and Immunotherapies

              Details:

              Proceeds from the Series B financing will be used to continue advancing the company’s MAPS pneumococcal vaccine program and to advance several additional vaccine candidates.

              Lead Product(s): MAPS Pneumococcal vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Viking Global Investors

              Deal Size: $120.0 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing April 23, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY